Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel.

MLA

Zanwar, Saurabh, et al. “Impact of Extramedullary Multiple Myeloma on Outcomes with Idecabtagene Vicleucel.” Journal of Hematology & Oncology, vol. 17, no. 1, June 2024, p. 42. EBSCOhost, https://doi.org/10.1186/s13045-024-01555-4.

APA

Zanwar, S., Sidana, S., Shune, L., Puglianini, O. C., Pasvolsky, O., Gonzalez, R., Dima, D., Afrough, A., Kaur, G., Davis, J. A., Herr, M., Hashmi, H., Forsberg, P., Sborov, D., Anderson, L. D., Jr, McGuirk, J. P., Wagner, C., Lieberman-Cribbin, A., Rossi, A., … Hansen, D. K. (2024). Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. Journal of Hematology & Oncology, 17(1), 42. https://doi.org/10.1186/s13045-024-01555-4

Chicago

Zanwar, Saurabh, Surbhi Sidana, Leyla Shune, Omar Castaneda Puglianini, Oren Pasvolsky, Rebecca Gonzalez, Danai Dima, et al. 2024. “Impact of Extramedullary Multiple Myeloma on Outcomes with Idecabtagene Vicleucel.” Journal of Hematology & Oncology 17 (1): 42. doi:10.1186/s13045-024-01555-4.